Bridge to Life™ Secures FDA De Novo Clearance for VitaSmart™ Hypothermic Oxygenated Perfusion (HOPE) System, the First Ever U.S. Approval for Cold Machine Perfusion in Liver Transplant Preservation

Bridge to Life™ Secures FDA De Novo Clearance for VitaSmart™ Hypothermic Oxygenated Perfusion (HOPE) System, the First Ever U.S. Approval for Cold Machine Perfusion in Liver Transplant Preservation VitaSmart Commercial Launch Expected

Bridge to Life™ Unveils Groundbreaking 12-Month Clinical Trial Data on HOPE at World Transplant Congress 2025

FOR IMMEDIATE RELEASE Bridge to Life™ Unveils Groundbreaking 12-Month Clinical Trial Data on HOPE at World Transplant Congress 2025 Pivotal Findings Spotlighted in Plenary Session, Late-Breaking Presentations, and Symposium on Next-Gen Liver

First-Ever Multicenter Study of Hypothermic Oxygenated Perfusion (HOPE) with VitaSmart™ in Pediatric Liver Transplants Confirms Safety and Favorable Outcomes

FOR IMMEDIATE RELEASE First-Ever Multicenter Study of Hypothermic Oxygenated Perfusion (HOPE) with VitaSmart™ in Pediatric Liver Transplants Confirms Safety and Favorable Outcomes Groundbreaking: The first multicenter study in any machine perfusion device,

New Data Analyses from Groundbreaking Pivotal Bridge to HOPE Clinical Trial Demonstrate Statistically Significant Clinical, Economic and Immunomodulatory Advantages in Liver Transplantation

FOR IMMEDIATE RELEASE New Data Analyses from Groundbreaking Pivotal Bridge to HOPE Clinical Trial Demonstrate Statistically Significant Clinical, Economic and Immunomodulatory Advantages in Liver Transplantation Presentations showcased at World Transplant Congress in

Bridge to Life Announces Abstract Presentations at The 2025 International Congress of the International Liver Transplantation Society (ILTS) in Singapore, May 28-31, 2025

Abstracts to highlight hypothermic oxygenated perfusion (HOPE) in liver transplants, including pediatric patients Chicago, May 15, 2025 Bridge to Life™ Ltd., a leader in organ preservation solutions and perfusion technology, today announced the

Italian Study Demonstrates Higher Utilization of Marginal Organs and Greater Transplantation Success in Patients at Higher Risk

At the 2024 ELITA Summit, an Italian study showcased remarkable advancements in liver transplantation, challenging long-standing perceptions of marginal donor organs. Led by Dr. Matteo Ravaioli and his team from

Two Independent Studies Representing Largest Real-World Experience with Hypothermic Oxygenated Machine Perfusion (HOPE) Reinforce Significant Benefits in Liver Preservation Before Transplantation, according to Bridge to Life Ltd.

Portuguese study confirms use of HOPE provides demonstrably improved liver graft utilization with reduced rates of non-anastomotic biliary stricture (NAS); Italian study demonstrates increasing experience in managing DCD (donation after

Bridge to Life Receives FDA 510(k) Clearance for Multi-Sourced Belzer UW® and MPS® Solutions with Expanded Labeling for MPS® Across All Abdominal Organs

Bridge to Life Receives FDA 510(k) Clearance for Multi-Sourced Belzer UW® and MPS® Solutions with Expanded Labeling for MPS® Across All Abdominal Organs Duluth, GA – October 7, 2025 – Bridge to